secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2026-06-25T12:01:26+00:00
Accession:  0001104659-26-077546
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure shareholders elect directors, approve amended equity plan with 80,000 additional shares
--------------------------------------------------------------------------------

- Anne Borgman, M.D. and John G. Houston, Ph.D. reelected as Class I directors for 3-year terms.
- Shareholders approved amendment and restatement of 2019 Omnibus Incentive Plan, increasing authorized shares by 80,000.
- Ratification of Ernst & Young LLP as independent auditor for fiscal 2026 passed with 2,774,832 votes for.
- Advisory vote on executive compensation passed with 2,109,269 votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926077546/0001104659-26-077546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000110465926077546/nxtc-20260618x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-077546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer